Anti-apoptotically active apatamers

Details Anti-apoptotically active apatamers Anti-apoptotically active apatamers

2004-12-10

2010-02-02

Epps-Smith, Janet L. (Department: 1633)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

07655773

ABSTRACT:
The invention relates to anti-apoptotically active apatamers. The invention describes possible therapeutic and diagnostic applications for, among other things, treating arteriosclerosis, promoting the healing of wounds, treating AIDS, cancer, Alzheimer's disease, systemic lupus erythematosus as well a rheumatoid arthritis and other chronic inflammatory diseases.

REFERENCES:
patent: 2005/0222020 (2005-10-01), Freyberg et al.
patent: 101 63 130 (2005-10-01), None
patent: WO 02/26932 (2002-04-01), None
patent: WO03/039484 (2003-05-01), None
patent: WO 03/054009 (2003-07-01), None
Genbank—Thrombospondin-1 (TSP-1) sequence.
TC1600 Memo—Interpreting claims with SEQ ID Nos.
Agrawal, “Antisense Oligonucleotides Towards Clinical Trials,”Tibtech, vol. 14, pp. 376-387, Oct. 1996.
Cerchia et al., “Nucleic Acid Aptamers in Cancer Medicine,”FEBS Letters, vol. 528, pp. 12-16, Aug. 28, 2002.
Ellington et al., “Aptamers as Potential Nucleic Acid Pharmaceuticals,”Biotechnology Annual Review, vol. 1, pp. 185-214, 1995.
Famulok, “Oligonucleotide Aptamers that Recognize Small Molecules,” pp. 324-329.
Freyberg et al., “Proatherogenic Flow Conditions Initiate Endothelial Apoptosis via Thrombospondin-1 and the Integrin-Associated Protein,”Biochemical and Biophysical Research Communications, vol. 286, pp. 141-149, 2001.
Gold et al., “Diversity of Oligonucleotide Functions,”Annu. Rev. Biochem., vol. 64, pp. 763-797, 1995.
Jayasena, “Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics,”Clinical Chemistry, vol. 45, No. 9, pp. 1628-1650, 1999.
Köhler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature, vol. 256, pp. 495-497, 1975.
Osborne et al., “Nucleic Acid Selection and the Challenge of Combinatorial Chemistry,”Chem. Rev., vol. 97, pp. 349-370, 1997.
Pieken et al., “Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes,”Science, vol. 253, pp. 314-317, Jul. 19, 1991.
Ruckman et al., “2′-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF 165),”The Journal of Biological Chemistry, vol. 273, No. 32, pp. 20556-20567, Aug. 7, 1998.
The Eyetech Study Group, “Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration,”The Journal of Retinal and Vitreous Diseases, vol. 22, No. 2, pp. 143-151, 2002.

Affiliated with

Also associated with

Rating

Anti-apoptotically active apatamers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-apoptotically active apatamers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-apoptotically active apatamers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4212906